Topics:

J&J scores 'breakthrough' status at FDA with cancer drug ibrutinib

Tools

Johnson & Johnson ($JNJ) and Pharmacyclics ($PCYC) nabbed the FDA's new breakthrough designation for their cancer drug ibrutinib, a promising late-stage therapy that will be put in the hands of regulators later this year. Report